Company CEO Dr. Tom Rau to present on high potential topical treatment for Shingles

This latest research highlights Solexan™’s promising activity against gram-positive bacteria (including antibiotic-resistant strains) and its potential as a treatment for impetigo and similar skin infections.

Understanding how Solexan™ works against viruses is a crucial step in bringing it to medical clinics and helping people with herpes infections.

Wintermute Biomedical raises $1.3 million USD, exceeding its target, to expand its Phase Ib trial and accelerate shingles treatment advancements.


Reaching the halfway point in the Phase 1B trial, Solexan™ shows promise as a novel topical therapy to ease shingles pain and accelerate recovery.

Antimicrobial GS-2 shows as a valuable application for minimizing single use plastics and foodborne risks associated with reusable packaging

Sad passing of founding Board director - Paul Cohn

Wintermute Biomedical Founder and CEO shares promising preclinical results on a novel fatty acid-based hydrogel for combating wound infections in military settings.

Urinary catheter market evaluation underscores the opportunity in the USA, emphasizes the benefit of strategic partnerships, and highlights potential patient populations suited for successful market entry.

Company CEO Dr. Tom Rau to present novel nano-micelle solution for combating biowarfare threats, traumatic wound infections, and drug-resistant pathogens

Wintermute Biomedical partners with the AMR Hub to advance the fight against antimicrobial resistance.

New partnership aims to test rapid antimicrobial intervention for traumatic wounds in combat zones.

Wintermute teams up with top surface scientist to create antimicrobial medical device coatings and combat widespread hospital infections.

Pioneering the way in Shingles therapy, Wintermute Biomedical initiates a Phase Ib clinical trial, backed by a successful $1.3M USD investment.

Breaking Ground in Shingles Treatment: Wintermute Biomedical Advances to Clinical Trials

Wintermute secures grant to partner with renowned Mycobacterium expert Professor Eric Nuermberger in pursuit of a breakthrough treatment for neglected Buruli ulcers.

Bridging innovation and opportunity: Wintermute Biomedical's spotlight at the BLUE KNIGHT™️ QuickPitch event

Wintermute's clinical advisory board gains the expertise of a renowned infectious disease expert, enhancing their efforts to combat shingles with their groundbreaking topical therapy Solexan™.

Wintermute joins forces with Dr. Fabian Kong at the University of Melbourne to combat the rise of multi-drug resistant oral gonorrhoea infections.

Wintermute Biomedical collaborates with Ten Carbon Chemistry to explore the potential of GS-2 in reusable food packaging with a $260,000 grant from the US Department of Agriculture.

Collaboration with Defence Science and Technology Group, Australia could be the start of a commercial venture for this antimicrobial biotech company.

Bringing innovative antimicrobial fatty acid formulations to agriculture and environmental industries.

Wintermute Biomedical's fatty acid formulation, GS-1, demonstrates anticancer activity. These findings were recently published in the International Journal of Molecular Sciences.

Our leading topical therapeutic passes first hurdle in shingles clinical pathway

GS-13 is our fatty acid formulation in development as a solution to systemic and antibiotic-resistant infections.

Testing of Wintermute’s topical antimicrobial therapy, Solexan™, at the State University of New York shows it has potent activity against Varicella Zoster Virus.

Novel inhalation therapy moves to animal trials in US $3 Billion fast-track COVID-19 treatments program under Dr Anthony Fauci.